Astellas is reintroducing its XLMTM gene therapy into clinical trials after previous incidents of patient deaths, while other biotech news highlights Veradermics' successful late-stage trial for a hair loss pill and promising results from Intellia's CRISPR therapy for hereditary angioedema.
Intellia Therapeutics' CRISPR-based treatment for hereditary angioedema has achieved significant results in a Phase 3 trial, reducing attack rates by 87% and positioning itself as a potential functional cure with no serious safety signals. This advancement highlights the promising potential of gene editing technologies in addressing rare genetic disorders, offering a strong signal for investment and collaboration opportunities in the biotech sector focused on precision medicine and gene therapy.